Related Experiment Video

Updated: Aug 1, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

VEGF-targeted therapy in metastatic renal cell carcinoma

Brian I Rini1

  • 11600 Divisadero, Room A717, San Francisco, California 94115, USA. brini@medicine.ucsf.edu

The Oncologist
|March 29, 2005
PubMed
Abstract

Insights

Targeting vascular endothelial growth factor (VEGF) in renal cell carcinoma (RCC) shows promise. Inactivation of the von Hippel-Lindau (VHL) gene leads to VEGF overexpression, and blocking VEGF demonstrates clinical activity in metastatic RCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Renal cell carcinoma (RCC) is a significant health concern.
  • The von Hippel-Lindau (VHL) gene plays a crucial role in RCC development.
  • VEGF overexpression is a common event in clear cell RCC.

Purpose of the Study:

  • To review the biology of renal cell carcinoma (RCC).
  • To examine the clinical outcomes of vascular endothelial growth factor (VEGF) blockade in metastatic RCC.

Main Methods:

  • Literature review of VHL gene inactivation and VEGF in RCC.
  • Review of VEGF-targeted therapy mechanisms, toxicity, and clinical trials in metastatic RCC.

Main Results:

  • VHL gene inactivation, observed in most clear cell RCC, results in VEGF overexpression.
  • VEGF-targeted therapies have shown initial clinical activity in metastatic RCC patients.

Conclusions:

  • Targeting VEGF in RCC has a strong biological basis.
  • VEGF-targeting agents demonstrate substantial clinical activity in early trials.
  • Further research is necessary to optimize the use of VEGF inhibitors for maximum patient benefit.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.